For the quarter ended September 2025, Gilead Sciences (GILD) reported revenue of $7.77 billion, up 3% over the same period last year. EPS came in at $2.47, compared to $2.02 in the year-ago quarter.
The reported revenue represents a surprise of +4.16% over the Zacks Consensus Estimate of $7.46 billion. With the consensus EPS estimate being $2.15, the EPS surprise was +14.88%.
While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.
Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.
Here is how Gilead performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
- Product Sales- HIV- Biktarvy- U.S.: $2.94 billion versus $2.91 billion estimated by three analysts on average. Compared to the year-ago quarter, this number represents a +4% change.
- Product Sales- HIV- Symtuza-Revenue share- U.S.: $95 million compared to the $93.47 million average estimate based on three analysts. The reported number represents a change of -7.8% year over year.
- Product Sales- Oncology- Cell Therapy- Yescarta- U.S.: $123 million compared to the $146.38 million average estimate based on three analysts. The reported number represents a change of -15.2% year over year.
- Product Sales- HIV- Odefsey- U.S.: $206 million versus $226.8 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a -16.9% change.
- Total product sales- Total: $7.35 billion compared to the $7.44 billion average estimate based on six analysts. The reported number represents a change of -2.3% year over year.
- Revenues- Royalty contract and other revenues: $424 million versus $36.64 million estimated by six analysts on average. Compared to the year-ago quarter, this number represents a +1313.3% change.
- Product Sales- Liver Disease- Vemlidy- Total: $280 million compared to the $238.21 million average estimate based on five analysts. The reported number represents a change of +20.7% year over year.
- Product Sales- Oncology- Cell Therapy- Yescarta- Total: $349 million versus the five-analyst average estimate of $401.01 million. The reported number represents a year-over-year change of -9.8%.
- Product Sales- HIV- Biktarvy- Total: $3.69 billion versus the five-analyst average estimate of $3.61 billion. The reported number represents a year-over-year change of +6.2%.
- Product Sales- HIV- Symtuza-Revenue share- Total: $124 million versus $125.24 million estimated by five analysts on average. Compared to the year-ago quarter, this number represents a -10.8% change.
- Product Sales- Veklury- Total: $277 million compared to the $344.43 million average estimate based on five analysts. The reported number represents a change of -60% year over year.
- Product Sales- HIV- Odefsey- Total: $277 million versus $286.61 million estimated by five analysts on average. Compared to the year-ago quarter, this number represents a -15% change.
View all Key Company Metrics for Gilead here>>>
Shares of Gilead have returned +6.6% over the past month versus the Zacks S&P 500 composite's +3.6% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Gilead Sciences, Inc. (GILD): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).
Zacks Investment Research
